Pulmonx Corp. (LUNG)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$2.56-9.54%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · LUNG
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -71.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 9.5% |
Growth built into the price is above our model estimate.
The price assumes 81.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 42 industry peers · Company calendar date is not available
LUNG — earnings in line
Dated 2026-04-29
Results of Operations and Financial Condition. On April 29, 2026, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2026. A copy of the Company’s press release dated April 29, 2026, titled “Pulmonx Reports First Quarter 2026 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “
Why it matters: Pulmonx raised its 2026 margin outlook from about 75% in Q1 to about 77% in Q3. The full-year result will test that improvement.
Supportive ifFull-year 2026 gross margin is 76% or higher, near the stated 77% outlook.
Worry ifFull-year 2026 gross margin is below 76%.
Why it matters: Q3 revenue rose 6% year over year after declines in Q1 and Q2. Another gain would show that growth has continued.
Supportive ifQ4 worldwide revenue exceeds $22.8 million and is above the same quarter last year.
Worry ifQ4 worldwide revenue is below the same quarter last year.
Why it matters: Pulmonx kept this full-year range after Q3 revenue growth returned. The result will show whether the recovery meets its stated goal.
Supportive ifFull-year 2026 revenue is at least $90 million and no more than $92 million.
Worry ifFull-year 2026 revenue is below $90 million or above $92 million.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$327 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $678 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,500 loss on $10,000 · 55.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.